ENTPD1 and neoplasm: demonstrated that CD39 inhibition sensitizes tumor-resistant models to anti-PD1, and that blocking CD39 activity is associated with the enrichment of cytotoxic T cells in the TME and upregulation of inflammatory markers on these infiltrates (105).